Literature DB >> 23042232

Cell surface complement regulators moderate experimental myasthenia gravis pathology.

Linda L Kusner1, Jose A Halperin, Henry J Kaminski.   

Abstract

INTRODUCTION: Intrinsic mouse complement regulators influence the severity of passively induced experimental acquired myasthenia gravis (EAMG). To assess the potential influence of CD59b in the absence of CD59a background, we used the mCD59ab(-/-) mouse model to re-evaluate mCD59 in protecting the neuromuscular junction (NMJ).
METHODS: EAMG was induced with monoclonal antibody to the acetylcholine receptor (AChR) in Daf1(-/-) , CD59ab(-/-) , Daf1(-/-) CD59ab(-/-) , and wild-type C57Bl/6 mice. Animals were monitored throughout the experiment. Diaphragms were analyzed for NMJ injury.
RESULTS: Daf1(-/-) CD59ab(-/-) mice required euthanasia 24 hours after disease induction because of severe weakness. Histological assessment demonstrated reduced AChR density, simplification of synaptic folds, and disrupted mitochondria. CD59ab-deficient mice demonstrated mild weakness and reduction in weight after 24 hours. In contrast, Daf1(-/-) had more severe weakness at 60 hours. The NMJ of EAMG-induced Daf1(-/-) and CD59ab(-/-) mice demonstrated similar AChR density.
CONCLUSION: NMJs of CD59 and DAF mice are protected from complement-mediated injury of passive EAMG.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23042232      PMCID: PMC4308955          DOI: 10.1002/mus.23448

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  38 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Complement regulators and inhibitory proteins.

Authors:  Peter F Zipfel; Christine Skerka
Journal:  Nat Rev Immunol       Date:  2009-09-04       Impact factor: 53.106

Review 3.  Development of novel therapies for MG: Studies in animal models.

Authors:  M C Souroujon; T Brenner; S Fuchs
Journal:  Autoimmunity       Date:  2010-08       Impact factor: 2.815

4.  Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies.

Authors:  F Lin; Y Fukuoka; A Spicer; R Ohta; N Okada; C L Harris; S N Emancipator; M E Medof
Journal:  Immunology       Date:  2001-10       Impact factor: 7.397

5.  Deficiency of the mouse complement regulatory protein mCd59b results in spontaneous hemolytic anemia with platelet activation and progressive male infertility.

Authors:  Xuebin Qin; Nicole Krumrei; Luciano Grubissich; Martin Dobarro; Huseyin Aktas; Graciela Perez; Jose A Halperin
Journal:  Immunity       Date:  2003-02       Impact factor: 31.745

6.  Structural factors influencing the efficacy of neuromuscular transmission.

Authors:  Clarke R Slater
Journal:  Ann N Y Acad Sci       Date:  2007-12-20       Impact factor: 5.691

7.  Analysis of the promoters and 5'-UTR of mouse Cd59 genes, and of their functional activity in erythrocytes.

Authors:  X Qin; S Ferris; W Hu; F Guo; G Ziegeler; J A Halperin
Journal:  Genes Immun       Date:  2006-03-16       Impact factor: 2.676

8.  Novel complement inhibitor limits severity of experimentally myasthenia gravis.

Authors:  Jindrich Soltys; Linda L Kusner; Andrew Young; Chelliah Richmonds; Denise Hatala; Bendi Gong; Vaithesh Shanmugavel; Henry J Kaminski
Journal:  Ann Neurol       Date:  2009-01       Impact factor: 10.422

9.  The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb.

Authors:  T Fujita; T Inoue; K Ogawa; K Iida; N Tamura
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

10.  Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein.

Authors:  Y U Kim; T Kinoshita; H Molina; D Hourcade; T Seya; L M Wagner; V M Holers
Journal:  J Exp Med       Date:  1995-01-01       Impact factor: 14.307

View more
  10 in total

1.  Guidelines for pre-clinical assessment of the acetylcholine receptor--specific passive transfer myasthenia gravis model-Recommendations for methods and experimental designs.

Authors:  Linda L Kusner; Mario Losen; Angela Vincent; Jon Lindstrom; Socrates Tzartos; Konstantinos Lazaridis; Pilar Martinez-Martinez
Journal:  Exp Neurol       Date:  2015-03-03       Impact factor: 5.330

Review 2.  Complementopathies and precision medicine.

Authors:  Eleni Gavriilaki; Robert A Brodsky
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

Review 3.  Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review.

Authors:  Jayne L Chamberlain; Saif Huda; Daniel H Whittam; Marcelo Matiello; B Paul Morgan; Anu Jacob
Journal:  J Neurol       Date:  2019-09-03       Impact factor: 4.849

Review 4.  The role of complement in experimental autoimmune myasthenia gravis.

Authors:  Linda L Kusner; Henry J Kaminski
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

Review 5.  Applying complement therapeutics to rare diseases.

Authors:  Edimara S Reis; Dimitrios C Mastellos; Despina Yancopoulou; Antonio M Risitano; Daniel Ricklin; John D Lambris
Journal:  Clin Immunol       Date:  2015-09-01       Impact factor: 3.969

Review 6.  Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms.

Authors:  William D Phillips; Angela Vincent
Journal:  F1000Res       Date:  2016-06-27

Review 7.  Complement Inhibitor Therapy for Myasthenia Gravis.

Authors:  Khaled Albazli; Henry J Kaminski; James F Howard
Journal:  Front Immunol       Date:  2020-06-03       Impact factor: 7.561

8.  Investigational RNAi Therapeutic Targeting C5 Is Efficacious in Pre-clinical Models of Myasthenia Gravis.

Authors:  Linda L Kusner; Kristina Yucius; Manjistha Sengupta; Andrew G Sprague; Dhruv Desai; Tuyen Nguyen; Klaus Charisse; Satya Kuchimanchi; Rajeev Kallanthottathil; Kevin Fitzgerald; Henry J Kaminski; Anna Borodovsky
Journal:  Mol Ther Methods Clin Dev       Date:  2019-05-10       Impact factor: 6.698

9.  Survivin as a potential mediator to support autoreactive cell survival in myasthenia gravis: a human and animal model study.

Authors:  Linda L Kusner; Michael J Ciesielski; Alexander Marx; Henry J Kaminski; Robert A Fenstermaker
Journal:  PLoS One       Date:  2014-07-22       Impact factor: 3.240

10.  Targeting therapy to the neuromuscular junction: proof of concept.

Authors:  Linda L Kusner; Namita Satija; Georgiana Cheng; Henry J Kaminski
Journal:  Muscle Nerve       Date:  2014-05       Impact factor: 3.217

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.